ANNX Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of -- compared to Annexon, Inc.'s net margin of -31.03%. Annexon, Inc.'s return on equity of -84.23% beat Agenus, Inc.'s return on equity of --.

Annexon, Inc. has a consensus price target of $13.71, signalling upside risk potential of 149.35%. On the other hand Agenus, Inc. has an analysts' consensus of $15.50 which suggests that it could grow by 270.37%. Given that Agenus, Inc. has higher upside potential than Annexon, Inc., analysts believe Agenus, Inc. is more attractive than Annexon, Inc..

Annexon, Inc. has a beta of 1.144, which suggesting that the stock is 14.415% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.604, suggesting its more volatile than the S&P 500 by 60.406%.

Annexon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annexon, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.

Annexon, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $34.2M. Annexon, Inc.'s net income of -$54.9M is lower than Agenus, Inc.'s net income of -$10.6M. Notably, Annexon, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annexon, Inc. is -- versus 0.88x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Annexon, Inc.'s net margin of 16.99%. Annexon, Inc.'s return on equity of -84.23% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Annexon, Inc. has a consensus price target of $13.71, signalling upside risk potential of 149.35%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that Annexon, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Annexon, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Annexon, Inc. has a beta of 1.144, which suggesting that the stock is 14.415% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.

Annexon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annexon, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Annexon, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Annexon, Inc.'s net income of -$54.9M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Annexon, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annexon, Inc. is -- versus 11.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

American Well Corp. has a net margin of -- compared to Annexon, Inc.'s net margin of -45.51%. Annexon, Inc.'s return on equity of -84.23% beat American Well Corp.'s return on equity of -33.17%.

Annexon, Inc. has a consensus price target of $13.71, signalling upside risk potential of 149.35%. On the other hand American Well Corp. has an analysts' consensus of $6.25 which suggests that it could grow by 13.64%. Given that Annexon, Inc. has higher upside potential than American Well Corp., analysts believe Annexon, Inc. is more attractive than American Well Corp..

Annexon, Inc. has a beta of 1.144, which suggesting that the stock is 14.415% more volatile than S&P 500. In comparison American Well Corp. has a beta of 1.389, suggesting its more volatile than the S&P 500 by 38.901%.

Annexon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. American Well Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annexon, Inc. pays -- of its earnings as a dividend. American Well Corp. pays out -- of its earnings as a dividend.

Annexon, Inc. quarterly revenues are --, which are smaller than American Well Corp. quarterly revenues of $55.3M. Annexon, Inc.'s net income of -$54.9M is lower than American Well Corp.'s net income of -$25.2M. Notably, Annexon, Inc.'s price-to-earnings ratio is -- while American Well Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annexon, Inc. is -- versus 0.37x for American Well Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Pacira Biosciences, Inc. has a net margin of -- compared to Annexon, Inc.'s net margin of 0.83%. Annexon, Inc.'s return on equity of -84.23% beat Pacira Biosciences, Inc.'s return on equity of 0.94%.

Annexon, Inc. has a consensus price target of $13.71, signalling upside risk potential of 149.35%. On the other hand Pacira Biosciences, Inc. has an analysts' consensus of $28.71 which suggests that it could grow by 26.5%. Given that Annexon, Inc. has higher upside potential than Pacira Biosciences, Inc., analysts believe Annexon, Inc. is more attractive than Pacira Biosciences, Inc..

Annexon, Inc. has a beta of 1.144, which suggesting that the stock is 14.415% more volatile than S&P 500. In comparison Pacira Biosciences, Inc. has a beta of 0.194, suggesting its less volatile than the S&P 500 by 80.617%.

Annexon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacira Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annexon, Inc. pays -- of its earnings as a dividend. Pacira Biosciences, Inc. pays out -- of its earnings as a dividend.

Annexon, Inc. quarterly revenues are --, which are smaller than Pacira Biosciences, Inc. quarterly revenues of $196.9M. Annexon, Inc.'s net income of -$54.9M is lower than Pacira Biosciences, Inc.'s net income of $1.6M. Notably, Annexon, Inc.'s price-to-earnings ratio is -- while Pacira Biosciences, Inc.'s PE ratio is 143.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annexon, Inc. is -- versus 1.40x for Pacira Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.